Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population

Detalhes bibliográficos
Autor(a) principal: Meireles-Brandão, Joaquim A.
Data de Publicação: 2019
Outros Autores: Meireles-Brandão, Lúcia R., Coelho, Rui, Rocha-Gonçalves, Francisco R.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251
Resumo: Introduction: High values of lipoprotein(a), related to atherosclerosis progression, are often considered a marker of thrombosis. We assessed the lipoprotein(a) profile in a group of patients with high vascular risk and no cardiovascular events, established its correlation with other cardiovascular risk factors and inferred the results for patients with metabolic disorders and, at least, two risk factors.Material and Methods: This longitudinal observational study included 516 patients, who had at least two cardiovascular risk factors and regularly attended, for at least two years, the outpatient consultations at a clinic of metabolism and vascular risk for primary prevention. Sociodemographic, clinical and anthropometric parameters were obtained at the baseline visit. Hepatic morphology was assessed in 509 patients (98.6%) by ultrasonography. The 10-year vascular risk was estimated using Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation tables.Results: Significant correlations were found between lipoprotein(a) levels and the addressed vascular risk factors, as well as between lipoprotein(a), and Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation charts. Lipoprotein(a) values were also considerably higher in patients with steatosis.Discussion: Increased lipoprotein(a) values were directly associated with all markers of cardiovascular risk and with non-alcoholic hepatic steatosis.Conclusion: Due to its high availability and low cost, lipoprotein(a) should become part of the routine evaluation of patients at vascular risk.
id RCAP_2cb624007eaf5c54148b3621e60aca6a
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/10251
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese PopulationLipoproteína(a) na Avaliação do Risco Cardiovascular na População PortuguesaAtherosclerosisCardiovascular DiseasesLipoprotein(a)PortugalPrimary PreventionAteroscleroseDoenças CardiovascularesLipoproteína(a)PortugalPrevenção PrimáriaIntroduction: High values of lipoprotein(a), related to atherosclerosis progression, are often considered a marker of thrombosis. We assessed the lipoprotein(a) profile in a group of patients with high vascular risk and no cardiovascular events, established its correlation with other cardiovascular risk factors and inferred the results for patients with metabolic disorders and, at least, two risk factors.Material and Methods: This longitudinal observational study included 516 patients, who had at least two cardiovascular risk factors and regularly attended, for at least two years, the outpatient consultations at a clinic of metabolism and vascular risk for primary prevention. Sociodemographic, clinical and anthropometric parameters were obtained at the baseline visit. Hepatic morphology was assessed in 509 patients (98.6%) by ultrasonography. The 10-year vascular risk was estimated using Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation tables.Results: Significant correlations were found between lipoprotein(a) levels and the addressed vascular risk factors, as well as between lipoprotein(a), and Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation charts. Lipoprotein(a) values were also considerably higher in patients with steatosis.Discussion: Increased lipoprotein(a) values were directly associated with all markers of cardiovascular risk and with non-alcoholic hepatic steatosis.Conclusion: Due to its high availability and low cost, lipoprotein(a) should become part of the routine evaluation of patients at vascular risk.Introdução: Valores elevados de lipoproteína(a), relacionados com a progressão da aterosclerose, são frequentemente considerados marcadores de trombose. O perfil de lipoproteína(a) foi avaliado num grupo de doentes sem eventos cardiovasculares mas com elevado risco vascular, estabelecendo-se a correlação com outros fatores de risco cardiovascular e inferindo-se os resultados para doentes com alterações metabólicas e, pelo menos, dois fatores de risco vascular.Material e Métodos: Este estudo observacional longitudinal incluiu 516 doentes com, pelo menos, dois fatores de risco cardiovascular e que frequentavam, regularmente e há pelo menos dois anos, a consulta ambulatória de metabolismo e risco vascular para prevenção primária. Os parâmetros sociodemográficos, clínicos e antropométricos foram recolhidos na primeira visita. A morfologia hepática foi avaliada por ultrassonografia em 509 doentes (98,6%). O risco vascular a 10 anos foi estimado através de tabelas de cálculo de risco de Framingham, doença cardiovascular e risco coronário sistemático.Resultados: Foram encontradas correlações significativas entre os níveis de lipoproteína(a) e os fatores de risco vasculares analisados, assim como entre lipoproteína(a) e as escalas de risco de Framingham, doença cardiovascular e risco coronário sistemático. Os valores de lipoproteína(a) apresentaram-se mais elevados em doentes com esteatose.Discussão: Os valores elevados de lipoproteína(a) estão diretamente associados com todos os marcadores de risco cardiovascular e com esteatose hepática não alcoólica.Conclusão: Como tal, considerando a sua elevada acessibilidade e custo reduzido, o marcador lipoproteína(a) deverá ser integrado na avaliação de rotina de doentes com risco vascular.Ordem dos Médicos2019-03-29info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/mswordapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251oai:ojs.www.actamedicaportuguesa.com:article/10251Acta Médica Portuguesa; Vol. 32 No. 3 (2019): March; 202-207Acta Médica Portuguesa; Vol. 32 N.º 3 (2019): Março; 202-2071646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/5654https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/9909https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/10744https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/10879Direitos de Autor (c) 2019 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessMeireles-Brandão, Joaquim A.Meireles-Brandão, Lúcia R.Coelho, RuiRocha-Gonçalves, Francisco R.2022-12-20T11:05:55Zoai:ojs.www.actamedicaportuguesa.com:article/10251Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:51.087428Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
Lipoproteína(a) na Avaliação do Risco Cardiovascular na População Portuguesa
title Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
spellingShingle Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
Meireles-Brandão, Joaquim A.
Atherosclerosis
Cardiovascular Diseases
Lipoprotein(a)
Portugal
Primary Prevention
Aterosclerose
Doenças Cardiovasculares
Lipoproteína(a)
Portugal
Prevenção Primária
title_short Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
title_full Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
title_fullStr Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
title_full_unstemmed Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
title_sort Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
author Meireles-Brandão, Joaquim A.
author_facet Meireles-Brandão, Joaquim A.
Meireles-Brandão, Lúcia R.
Coelho, Rui
Rocha-Gonçalves, Francisco R.
author_role author
author2 Meireles-Brandão, Lúcia R.
Coelho, Rui
Rocha-Gonçalves, Francisco R.
author2_role author
author
author
dc.contributor.author.fl_str_mv Meireles-Brandão, Joaquim A.
Meireles-Brandão, Lúcia R.
Coelho, Rui
Rocha-Gonçalves, Francisco R.
dc.subject.por.fl_str_mv Atherosclerosis
Cardiovascular Diseases
Lipoprotein(a)
Portugal
Primary Prevention
Aterosclerose
Doenças Cardiovasculares
Lipoproteína(a)
Portugal
Prevenção Primária
topic Atherosclerosis
Cardiovascular Diseases
Lipoprotein(a)
Portugal
Primary Prevention
Aterosclerose
Doenças Cardiovasculares
Lipoproteína(a)
Portugal
Prevenção Primária
description Introduction: High values of lipoprotein(a), related to atherosclerosis progression, are often considered a marker of thrombosis. We assessed the lipoprotein(a) profile in a group of patients with high vascular risk and no cardiovascular events, established its correlation with other cardiovascular risk factors and inferred the results for patients with metabolic disorders and, at least, two risk factors.Material and Methods: This longitudinal observational study included 516 patients, who had at least two cardiovascular risk factors and regularly attended, for at least two years, the outpatient consultations at a clinic of metabolism and vascular risk for primary prevention. Sociodemographic, clinical and anthropometric parameters were obtained at the baseline visit. Hepatic morphology was assessed in 509 patients (98.6%) by ultrasonography. The 10-year vascular risk was estimated using Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation tables.Results: Significant correlations were found between lipoprotein(a) levels and the addressed vascular risk factors, as well as between lipoprotein(a), and Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation charts. Lipoprotein(a) values were also considerably higher in patients with steatosis.Discussion: Increased lipoprotein(a) values were directly associated with all markers of cardiovascular risk and with non-alcoholic hepatic steatosis.Conclusion: Due to its high availability and low cost, lipoprotein(a) should become part of the routine evaluation of patients at vascular risk.
publishDate 2019
dc.date.none.fl_str_mv 2019-03-29
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251
oai:ojs.www.actamedicaportuguesa.com:article/10251
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/10251
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/5654
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/9909
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/10744
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/10879
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2019 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2019 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/msword
application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 32 No. 3 (2019): March; 202-207
Acta Médica Portuguesa; Vol. 32 N.º 3 (2019): Março; 202-207
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130648358682624